New insulin shows promise for type 1 diabetes in chinese trial
NCT ID NCT07282054
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested a new fast-acting insulin called THDB0206 against a standard insulin (lispro) in 550 Chinese adults with type 1 diabetes. Both groups also used a long-acting insulin (glargine). The main goal was to see if THDB0206 could control blood sugar (HbA1c) as well as the standard treatment over 26 weeks. The study is complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
THDB0206 (a fast-acting insulin)
What this could lead to
If it works, this could offer a new fast-acting insulin option for people with type 1 diabetes, potentially improving blood sugar control.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. It only included Chinese adults, so findings may not apply to other populations. As with any insulin, risks include low blood sugar and injection site reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Drum Tower hospital
Nanjing, China